MP0712 — Topline data
2026
• DLL3-targeting Radio-DARPin MP0712 progressing in Phase 1/2a trial, now recruiting at dose level 2; initial data expected in 2026, efficacy data expected in 2027Source filing
MOLN biotech catalysts & pipeline
MOLECULAR PARTNERS AG · Data as of 2026-09-08
Upcoming catalysts
MP0533 — Interim data
Summer 2026
Data on MP0533, our multispecific T cell engager for relapsed/refractory acute myeloid leukemia, showed that densified dosing is tolerable and leads to improved exposure and mutation-agnostic antitumor activity, and will update on the clinical development path of MP0533 by Summer 2026.Source filing
MP0726 — Initial data
H2 2026
The Company communicated in July 2026 that it intends to advance MSLN-targeting MP0726, its second RDT program, to first-in-human imaging in H2 2026.Source filing
MP0317 — Interim data
2027
Data update expected in 2027, with trial completion in 2028Source filing
MP0712 — Full data
2027
• DLL3-targeting Radio-DARPin MP0712 progressing in Phase 1/2a trial, now recruiting at dose level 2; initial data expected in 2026, efficacy data expected in 2027Source filing
CD70-targeting radiopharmaceutical therapy — Conference presentation
H2 2026
The Company intends to present supporting pre-clinical data at a scientific congress in H2 2026.Source filing
MP0317 — Conference presentation
Oct 23–Oct 27
Trial-in-progress poster to be presented at ESMO 2026 in OctoberSource filing
MP0632 — Conference presentation
Nov 4–Nov 8
The Company will present additional pre-clinical data on MP0632 at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November 2026.Source filing